BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7370989)

  • 1. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
    Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
    Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
    Von Hoff DD; Myers JW; Kuhn J; Sandbach JF; Pocelinko R; Clark G; Coltman CA
    Cancer Res; 1981 Aug; 41(8):3118-21. PubMed ID: 6265075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
    Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
    Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
    Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
    Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.
    Alberts DS; Griffith KS; Goodman GE; Herman TS; Murray E
    Cancer Chemother Pharmacol; 1980; 5(1):11-5. PubMed ID: 7460190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
    Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
    Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.
    Wallace RE; Murdock KC; Angier RB; Durr FE
    Cancer Res; 1979 May; 39(5):1570-4. PubMed ID: 427798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of mitoxantrone by 24-hour continuous infusion.
    Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
    Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mitoxantrone HCl (1,4-dihydroxy-4, 8-bis[[2-(hydroxyethyl)-amino-ethyl)]amino 9,10-anthracenedione dihydrochloride (NSC 301739) - a new cytostatic].
    Hagenberg L; Loynds P; Nagel GA
    Onkologie; 1980 Dec; 3(6):322-8. PubMed ID: 6784060
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I trial of dihydroxyanthracenedione.
    Van Echo DA; Whitacre MY; Aisner J; Wiernik PH
    Cancer Treat Rep; 1981; 65(9-10):831-4. PubMed ID: 7273015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.
    Spiegel RJ; Blum RH; Levin M; Pinto CA; Wernz JC; Speyer JL; Hoffman KS; Muggia FM
    Cancer Res; 1982 Jan; 42(1):354-8. PubMed ID: 7053862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
    Taylor SA; Tranum BT; Von Hoff DD; Costanzi JJ
    Invest New Drugs; 1985; 3(1):67-9. PubMed ID: 3988458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
    Dorr FA; Von Hoff DD; Kuhn JG; Schwartz R; Kisner DL
    Cancer Res; 1986 May; 46(5):2562-5. PubMed ID: 2938729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of mitoxantrone in head and neck cancer.
    Aapro MS; Alberts DS
    Invest New Drugs; 1984; 2(3):329-30. PubMed ID: 6511239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical kinetics of 1, 4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione.
    Savaraj N; Lu K; Valdivieso M; Burgess M; Umsawasdi T; Benjamin RS; Loo TL
    Clin Pharmacol Ther; 1982 Mar; 31(3):312-6. PubMed ID: 7060314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and indirect clastogenic activity of anthracenedione in Chinese hamster ovary cells.
    Rosenberg LJ; Hittelman WN
    Cancer Res; 1983 Jul; 43(7):3270-5. PubMed ID: 6850635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.